An Antibody‐CRISPR/Cas Conjugate Platform for Target‐Specific Delivery and Gene Editing in Cancer

Abstract The CRISPR/Cas system has been introduced as an innovative tool for therapy, however achieving specific delivery to the target has been a major challenge. Here, an antibody‐CRISPR/Cas conjugate platform that enables specific delivery and target gene editing in HER2‐positive cancer is introd...

Descripció completa

Dades bibliogràfiques

Autors principals:	Seungju Yang, San Hae Im, Ju Yeon Chung, Juhee Lee, Kyung‐Hun Lee, Yoo Kyung Kang, Hyun Jung Chung
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2024-06-01
Col·lecció:	Advanced Science
Matèries:	antibody conjugation cancer therapy CRISPR/Cas in vivo gene editing specific delivery
Accés en línia:	https://doi.org/10.1002/advs.202308763
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!